綠康生化(002868.SZ):擬使用額度不超1億元自有資金進行現金管理
格隆匯 11 月 27日丨綠康生化(002868.SZ)公佈,為提高自有資金的使用效率,合理利用暫時閒置自有資金,獲取較好的投資回報,公司於2020年11月27日召開的第三屆董事會第二十二次(臨時)會議審議通過了《關於使用閒置自有資金進行現金管理的議案》。根據公司經營發展計劃和資金狀況,在確保資金安全、操作合法合規、保證正常生產經營不受影響的前提下,公司擬使用額度不超過人民幣1億元的自有資金購買安全性高、流動性好的金融機構理財產品,進行現金管理額度的使用期限為2021年1月1日至2021年12月31日,上述額度在期限內,公司按實際情況進行額度分配,資金滾動使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.